title: Cost-effectiveness analysis of rosuvastatin vs generic atorvastatin in Spain.
abstract: OBJECTIVE
  The objective of this study was to carry out a long-term cost-effectiveness analysis of rosuvastatin compared with generic atorvastatin in the treatment of patients at high cardiovascular (CV) risk (≥ 5% Systematic COronary Risk Evaluation [SCORE]) and patients with prior cardiovascular disease (CVD) in Spain.
  
  
  METHODS
  The efficacy data from the Statin Therapies for Elevated Lipid Levels compared Across doses to Rosuvastatin (STELLAR) study were used to simulate achievement of low-density lipoprotein cholesterol targets with different doses of rosuvastatin and generic atorvastatin for an initial period of 1 year. A Markov model was used to estimate the number of CV complications, quality-adjusted life years (QALYs), and healthcare costs (lipid-lowering treatment and CV events) for up to 20 years after initial treatment. The analysis was carried out from the perspective of the Spanish National Health System, with costs (in year 2010 euros) and effects being discounted at 3% per year.
  
  
  RESULTS
  Compared with generic atorvastatin, rosuvastatin was cost-effective (cost per QALY gained of less than €30,000) for the primary prevention of CV events in high-risk patients in most sub-groups analyzed. In patients with prior CVD, rosuvastatin was cost-effective in all sub-groups of men and most sub-groups of women. Key limitations of this study were the need to extrapolate data from a single trial to long-term modeled outcomes and the absence of other treatment options in the analysis.
  
  
  CONCLUSIONS
  For the treatment of dyslipidemic patients with high CV risk, rosuvastatin is more effective than generic atorvastatin in terms of survival and quality-of-life adjusted survival, with incremental cost-effectiveness ratios within the range generally used in Spain, in most sub-populations defined by various combinations of CV risk factors.
authors.affiliation: Cardiology Department, Hospital Ramón y Cajal  ,   Madrid  ,   Spain.
authors.forename: Vivencio
authors.initials: V
authors.lastname: Barrios
authors.forename: José M
authors.initials: JM
authors.lastname: Lobos
authors.forename: Adalberto
authors.initials: A
authors.lastname: Serrano
authors.forename: Max
authors.initials: M
authors.lastname: Brosa
authors.forename: Margarita
authors.initials: M
authors.lastname: Capel
authors.forename: Concha
authors.initials: C
authors.lastname: Alvarez Sanz
mesh_terms: D000328:Adult; D000368:Aged; D000069059:Atorvastatin; D002318:Cardiovascular Diseases / Q000517:prevention & control; D003362:Cost-Benefit Analysis; D016568:Drugs, Generic / Q000191:economics*; D050171:Dyslipidemias / Q000188:drug therapy; D005260:Female; D005464:Fluorobenzenes / Q000191:economics* / Q000627:therapeutic use; D006538:Heptanoic Acids / Q000191:economics* / Q000627:therapeutic use; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000191:economics* / Q000627:therapeutic use; D008297:Male; D008390:Markov Chains; D008875:Middle Aged; D011322:Primary Prevention; D011743:Pyrimidines / Q000191:economics* / Q000627:therapeutic use; D011758:Pyrroles / Q000191:economics* / Q000627:therapeutic use; D000068718:Rosuvastatin Calcium; D055502:Secondary Prevention; D013030:Spain; D013449:Sulfonamides / Q000191:economics* / Q000627:therapeutic use
chemical_list: D016568:Drugs, Generic; D005464:Fluorobenzenes; D006538:Heptanoic Acids; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors; D011743:Pyrimidines; D011758:Pyrroles; D013449:Sulfonamides; D000068718:Rosuvastatin Calcium; D000069059:Atorvastatin